Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Tra
Go back to Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Tra| (NASDAQ: KOD) | Delayed: 33.80 +1.38 (4.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.42 | 52 Week High | $ | |||
| Open | $32.71 | 52 Week Low | $ | |||
| Day High | $34.45 | P/E | N/A | |||
| Day Low | $32.46 | EPS | $ | |||
| Volume | 1,038,342 | |||||
